Skin Debridement without CC/MCC DRG Reimbursement Guide

DRG 572 includes inpatient skin debridement procedures without Complications or Comorbidities or Major Complications or Comorbidities, focusing on uncomplicated removal of necrotic or infected tissue. It matters for inpatient reimbursement because it defines the bundled Medicare payment for stays with lower expected resource utilization.

DRG 572 Overview

DRG 572 covers inpatient stays involving skin debridement procedures when there are no Complications or Comorbidities and no Major Complication or Comorbidity present. Typical cases include surgical removal of necrotic or infected skin and soft tissue without other significant diagnoses that would increase resource use. This Diagnosis-Related Group matters for Medicare payment because it establishes the bundled payment amount for these straightforward debridement admissions. Correct coding and documentation determine assignment to this group and the associated inpatient reimbursement level.

Acute procedural optimization studies: randomized or prospective trials comparing different operative and non-operative debridement techniques (sharp surgical debridement, hydrosurgical debridement, enzymatic debridement, or pulse lavage) performed in the inpatient setting for patients with extensive necrotic wounds, pressure ulcers, or complicated lacerations. These studies enroll patients at the time of admission who require immediate wound bed preparation and aim to measure time to viable granulation tissue, need for repeat debridement, infection control, and short-term resource utilization (operating room time, antibiotic days, and length of stay). Results inform clinicians about procedural efficacy and safety and help payers project costs and appropriate bundling of inpatient debridement services under this DRG.
Comparative effectiveness trials of adjunctive wound therapies combined with debridement: pragmatic studies that compare outcomes when standard inpatient debridement is followed by different adjuncts such as advanced dressings, negative pressure wound therapy, or biologic wound matrices in subgroups like diabetic foot wounds, venous stasis ulcers with cellulitis, or traumatic soft-tissue defects. These trials focus on healing rates, reoperation or readmission within 30 days, and total inpatient-to-post-discharge care costs, enrolling patients after initial debridement to evaluate which adjuncts reduce complications and accelerate recovery. Findings are directly relevant to providers choosing post-debridement pathways and to payers interested in interventions that reduce downstream utilization and readmissions within the DRG population.
Post-discharge outcomes and care-transition studies: cohort or interventional studies assessing the impact of discharge planning, early outpatient wound clinic follow-up, home health nursing, or telemedicine wound monitoring on readmission rates, wound healing trajectory, and total episode-of-care costs for patients discharged after inpatient debridement (often older adults, those with mobility limitations, or patients with comorbid diabetes or peripheral vascular disease). These studies track 30- and 90-day outcomes, patient adherence to wound care, and emergency department visits to identify high-risk subgroups and effective transitional care models. Results guide hospital quality improvement, reduce preventable readmissions that affect reimbursement, and inform payers about care coordination investments that can lower overall expenditures for this DRG.

Acute procedural optimization studies: randomized or prospective trials comparing different operative and non-operative debridement techniques (sharp surgical debridement, hydrosurgical debridement, enzymatic debridement, or pulse lavage) performed in the inpatient setting for patients with extensive necrotic wounds, pressure ulcers, or complicated lacerations. These studies enroll patients at the time of admission who require immediate wound bed preparation and aim to measure time to viable granulation tissue, need for repeat debridement, infection control, and short-term resource utilization (operating room time, antibiotic days, and length of stay). Results inform clinicians about procedural efficacy and safety and help payers project costs and appropriate bundling of inpatient debridement services under this DRG.
Comparative effectiveness trials of adjunctive wound therapies combined with debridement: pragmatic studies that compare outcomes when standard inpatient debridement is followed by different adjuncts such as advanced dressings, negative pressure wound therapy, or biologic wound matrices in subgroups like diabetic foot wounds, venous stasis ulcers with cellulitis, or traumatic soft-tissue defects. These trials focus on healing rates, reoperation or readmission within 30 days, and total inpatient-to-post-discharge care costs, enrolling patients after initial debridement to evaluate which adjuncts reduce complications and accelerate recovery. Findings are directly relevant to providers choosing post-debridement pathways and to payers interested in interventions that reduce downstream utilization and readmissions within the DRG population.
Post-discharge outcomes and care-transition studies: cohort or interventional studies assessing the impact of discharge planning, early outpatient wound clinic follow-up, home health nursing, or telemedicine wound monitoring on readmission rates, wound healing trajectory, and total episode-of-care costs for patients discharged after inpatient debridement (often older adults, those with mobility limitations, or patients with comorbid diabetes or peripheral vascular disease). These studies track 30- and 90-day outcomes, patient adherence to wound care, and emergency department visits to identify high-risk subgroups and effective transitional care models. Results guide hospital quality improvement, reduce preventable readmissions that affect reimbursement, and inform payers about care coordination investments that can lower overall expenditures for this DRG.

OpenPayer

Summary & Overview

Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

DRG 572 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes